Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide in Parenteral Nutrition-Dependent Short Bowel Syndrome
NCT00081458Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2004
- Primary completion
- Jul 2007
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of teduglutide in short bowel syndrome (SBS) (3 arms), sponsored by Takeda. Primary endpoint: Graded Response Score in Parenteral Nutrition Reduction at 6 months. Started May 2004; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT00081458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081458.